Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Reddy JA, Nelson M, Dircksen C, Vetzel M, Johnson T, Cross V, Westrick E, Qi L, Hahn S, Santhapuram HK, Parham G, Wang K, Vaughn JF, Felten A, Pugh M, Lu J, Klein P, Vlahov IR, Leamon CP.
Reddy JA, et al.
Sci Rep. 2020 Jul 29;10(1):12772. doi: 10.1038/s41598-020-69682-9.
Sci Rep. 2020.
PMID: 32728172
Free PMC article.